0.672
4.98%
+0.0319
Bioline Rx Ltd ADR stock is currently priced at $0.672, with a 24-hour trading volume of 4,209.
It has seen a +4.98% increased in the last 24 hours and a -43.05% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.6387 pivot point. If it approaches the $0.6925 resistance level, significant changes may occur.
Bioline Rx Ltd ADR Stock (BLRX) Financials Data
Bioline Rx Ltd ADR (BLRX) Net Income 2024
BLRX net income (TTM) was -$60.61 million for the quarter ending December 31, 2023, a -142.93% decrease year-over-year.
Bioline Rx Ltd ADR (BLRX) Cash Flow 2024
BLRX recorded a free cash flow (TTM) of -$22.91 million for the quarter ending December 31, 2023, a +13.75% increase year-over-year.
Bioline Rx Ltd ADR (BLRX) Earnings per Share 2024
BLRX earnings per share (TTM) was -$0.90 for the quarter ending December 31, 2023, a -100.00% decline year-over-year.
About Bioline Rx Ltd ADR
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Cap:
|
Volume (24h):